Tian Zhang, MD

Associate Professor of Medicine

Member of the Duke Cancer Institute

Campus mail DUMC 103861, Durham, NC 27710

Phone (919) 668-4667

Email address tian.zhang2@duke.edu

Education and Training

Fellowship in Hematology-Oncology, Medicine, Duke University School of Medicine, 2012 - 2015
Internal Medicine Residency, Medicine, Duke University School of Medicine, 2009 - 2012
M.H.S., Duke University School of Medicine, 2019
M.D., Harvard Medical School, 2009

Grants

A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERABLE, LOCALLY ADVANCED, OR METASTATIC RENAL CELL CARCIN
NeoImmune NMTNT110
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma (Mirati 516-003)
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
A Salvage Trial of AR Inhibition with ADT and Apalutamide with Docetaxel followed by Radiation Therapy in Men with PSA Recurrent Prostate Cancer after Radical Prostatectomy (¿STARTAR¿)
The impact of genetic diversity among Akkermansia strains on the effectivenes of immune checkpoint inhibitors in cancer immunotherapies
Phase II study of AGS-16C3F vs Axitinib in Metastatic Renal Cell Carcinoma
Immune correlates of immunotherapy responses in renal cell carcinoma
Predicting patient-specific responses to personalize androgen deprivation therapy for prostate cancer
A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF A VACCINE-BASED IMMUNOTHERAPY REGIMEN (VBIR) FOR PROSTATE CANCER (PF-06753512)
A Phase 1b, open label, prospective, non-randomized,single center study of conditional lethalithy to copper as a therapeutic modality in prostate cancer
Conditional lethality of copper and disulfiram as a therapeutic modality for prostate cancer

Publications

Bu, Jiyoon, Michael J. Poellmann, Marco Reyes-Martinez, Andrew Armstrong, Daniel George, Tian Zhang, Andrew Z. Wang, and seungpyo hong. “Abstract 6439: CapioCyte™ technology for efficient capture and downstream analysis of circulating tumor cells from renal cell carcinoma.” In Clinical Trials. American Association for Cancer Research, 2020. https://doi.org/10.1158/1538-7445.am2020-6439.

Full Text

Zhang, Tian, and Andrew Armstrong. “CLINICAL TRIALS IN PROGRESS.” Oncology New York 34, no. 8 (August 2020): 304–304.

Scholars@Duke

Zhang, Tian, Sarabjot Pabla, Felicia L. Lenzo, Jeffrey M. Conroy, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, et al. “Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients.” Oncoimmunology 9, no. 1 (June 10, 2020): 1773200. https://doi.org/10.1080/2162402X.2020.1773200.

PMID

32923131

Full Text

Bakthavatsalam, Subha, Petpailin Wiangnak, Daniel J. George, Tian Zhang, and Katherine J. Franz. “Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancer.” Bioorg Med Chem Lett 30, no. 11 (June 1, 2020): 127148. https://doi.org/10.1016/j.bmcl.2020.127148.

PMID

32253061

Full Text

Brown, Landon Carter, Ramy Sedhom, Eric B. Schwartz, Jason Zhu, Chester Kao, Matthew D. Tucker, Matthew Labriola, et al. “Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types.” In Journal of Clinical Oncology, Vol. 38, 2020.

Scholars@Duke

Battle, Dena, Cristiane Decat Bergerot, Pavlos Msaouel, Tian Zhang, Daniel J. George, and Michael D. Staehler. “Patient-reported use of marijuana and cannabinoid (CBD) oil in patients with renal cell carcinoma undergoing systemic therapy.” In Journal of Clinical Oncology, Vol. 38, 2020.

Scholars@Duke

Battle, Dena, Cristiane Decat Bergerot, Pavlos Msaouel, Eric Jonasch, Tian Zhang, Daniel J. George, and Michael D. Staehler. “Patient preferences and expectations of systemic therapy in renal cell carcinoma.” In Journal of Clinical Oncology, Vol. 38, 2020.

Scholars@Duke

Garmezy, Benjamin, Tian Zhang, Andrew Leonard Laccetti, Minas P. Economides, Amishi Yogesh Shah, Nizar M. Tannir, Eric Jonasch, et al. “Combination therapy with nivolumab and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.” In Journal of Clinical Oncology, Vol. 38, 2020.

Scholars@Duke

Zhang, Tian, Karla V. Ballman, Atish Dipankar Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen, Ardaman Shergill, et al. “PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).” In Journal of Clinical Oncology, Vol. 38, 2020.

Scholars@Duke

Campbell, Matthew T., Tian Zhang, Lynda Chin, Allison Betof Warner, and Matthen Mathew. “ApricityRx companion digital therapeutic for evidence-based mitigation and phenotype-linked molecular characterization of irAEs in patients receiving immune checkpoint therapy (ICT).” In Journal of Clinical Oncology, Vol. 38, 2020.

Scholars@Duke

Tian Zhang, MD

Education and Training

Grants

Publications

Pages